In October 2020, the Pharmaceutical Advertising Advisory Board (PAAB) released an advisory addressing references to “no sub” or “no substitution” in advertising materials. The advisory states that advertisers are permitted to indicate in promotional material that prescribers can write “no sub” on a prescription but should not suggest that writing “no sub” will guarantee that the patient will receive the prescribed brand name product. A patient may not end up receiving such product for a variety of reasons, including the patient opting for a generic product and due to conditions for reimbursement. A disclaimer indicating limitations and conditions should also be included as part of the fair balance requirement under the PAAB Code of Advertising Acceptance. The advisory provides an example of language that is acceptable and language that is not acceptable to include in promotional material and an example of a disclaimer.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Quebec Court finds price and revenue calculation provisions of amended PMPRB Regulations unconstitutional
The Quebec Superior Court issued its decision from a constitutional challenge to the PMPRB provisions of the Patent Act and the Regulations, including the amended Regulations.Read More -
Amendments to PMPRB Regulations will now be in force July 1, 2021
While scheduled to come into force on January 1, 2021 (see here), in recognition of the fact that the COVID-19 pandemic continues to challenge all stakeholders, the amendments to the Patented Medicine...Read More -
2020 Highlights in Canadian Life Sciences IP and Regulatory Law
In 2020, Rx IP Update reported on a number of developments in Canadian life sciences IP and regulatory law.Read More